Core Insights - Lisata Therapeutics and WARPNINE have completed patient enrollment in the Phase 1b/2a iLSTA trial, evaluating certepetide in combination with standard-of-care chemotherapy and immunotherapy for locally advanced non-resectable pancreatic ductal adenocarcinoma (PDAC) [1][2] - The trial is significant as it targets an earlier stage of PDAC, where immunotherapy has been largely ineffective [2] - Preliminary data from the trial presented at ESMO-GI indicated a 60% overall response rate and a 100% overall disease control rate after four treatment cycles [3][4] Company Overview - Lisata Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases [7] - Certepetide, the company's proprietary product candidate, is designed to enhance the delivery of anti-cancer drugs to solid tumors and has shown favorable safety and clinical activity in trials [6][7] - The company has received multiple designations for certepetide, including Fast Track and Orphan Drug Designations for pancreatic cancer in the U.S. and E.U. [6] Trial Details - The iLSTA trial is randomized, single-blind, and conducted at St John of God Subiaco Hospital, a leading center for clinical research in Australia [2][3] - Participants were divided into three cohorts, with varying combinations of standard-of-care chemotherapy and immunotherapy [2] - The trial aims to assess the efficacy of certepetide in improving treatment outcomes for patients with locally advanced PDAC [2][4] Preliminary Data Highlights - After four treatment cycles, 13 out of 20 participants showed a partial response, and one participant exhibited a complete response [3] - 16 out of 20 participants experienced a decrease in CA19-9 levels, a tumor marker, with several showing significant reductions [3] - No participants showed an increase in tumor size, indicating a positive response to the treatment [3] Collaboration and Support - The collaboration between Lisata and WARPNINE combines global expertise with local clinical execution to address urgent needs in pancreatic cancer treatment [2] - AstraZeneca is involved in providing drug supply, enhancing the trial's operational capabilities [2] - The successful completion of patient enrollment reflects the commitment of both organizations to advance treatment options for patients with PDAC [4]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive's content includes insights across various sectors such as biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced and qualified news journalists who produce independent content [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The news team delivers insights across various sectors including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

Core Viewpoint - The strategic alliance between Lisata Therapeutics and GATC Health aims to enhance drug development success rates by leveraging GATC's AI-powered Multiomics Advanced Technology® platform, with a focus on advancing a therapeutic for opioid use disorder into human clinical trials by early 2026 [1][3][4]. Company Overview - Lisata Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and serious diseases, with a notable product candidate, certepetide, designed to improve targeting of solid tumors [8]. - GATC Health Corp. is a technology company that utilizes AI to transform drug discovery and development, with its MAT platform capable of simulating human biochemistry to create novel therapeutics and predict drug efficacy and safety [9][11]. Collaboration Details - The collaboration builds on previous work where GATC provided AI-derived analysis for Lisata's certepetide candidate, and under the expanded relationship, Lisata will utilize GATC's MAT platform to identify new combination therapies across various therapeutic areas [2][3]. - Lisata will lead the development of a non-opioid small molecule candidate for opioid use disorder, which has shown significant efficacy in preclinical studies by reducing fentanyl intake in animal models [3][12]. Financial and Strategic Implications - The partnership is expected to create substantial value for the pharmaceutical industry, with predictions suggesting AI technologies could generate $350 to $400 billion by the end of 2025, while also significantly shortening the drug discovery timeline [4]. - GATC will cover all R&D costs for its development assets, while Lisata will receive milestone fees and royalties from any successfully commercialized products, indicating a financially symbiotic relationship [7]. Technology Validation - GATC's MAT platform has demonstrated high predictive accuracy, with sensitivity at 86% and specificity at 91%, validated by the University of California, Irvine, positioning it to meet FDA requirements for new methodologies prioritizing human-relevant data [5][11].

BASKING RIDGE, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata, will present a corporate overview at the upcoming 2025 BIO International Convention taking place in Boston, MA from June 16 – 19, 2025. Dr. Mazzo’s pre ...

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced and qualified news journalists who produce independent content [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content includes insights across various sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

Core Insights - Lisata Therapeutics is making significant progress in its clinical development portfolio, particularly with the drug certepetide, despite challenges in the small-cap healthcare market [2][3] - The company has extended its cash runway into the third quarter of 2026, maintaining a strong financial position with no debt [1][11] Clinical Development Highlights - Certepetide is being evaluated in multiple clinical trials for solid tumors, showing promising results in Cohort A of the ASCEND trial, with a positive trend in overall survival [3][4] - Cohort B results from the ASCEND trial are anticipated soon, with preliminary data accepted for presentation at the ESMO Gastrointestinal Cancers Congress [4] - The BOLSTER trial for cholangiocarcinoma has completed enrollment ahead of schedule, with topline data expected in mid-2025 [4] - The CENDIFOX trial has completed enrollment, providing valuable data for immune profiling and long-term patient outcomes [4] - The iLSTA trial is on track for completion, with preliminary results indicating that certepetide enhances immunotherapy effectiveness [4] Financial Performance - For Q1 2025, operating expenses decreased to $5.8 million from $6.6 million in Q1 2024, a reduction of 11.4% [7] - Research and development expenses were approximately $2.6 million, down 19.7% from $3.2 million in the same period last year [8] - General and administrative expenses slightly decreased to $3.2 million from $3.4 million year-over-year [9] - The net loss for Q1 2025 was $4.7 million, compared to $5.4 million in Q1 2024 [10] Balance Sheet Overview - As of March 31, 2025, the company had cash, cash equivalents, and marketable securities totaling approximately $25.8 million [11] - Total liabilities were reported at $3.9 million, with total equity at $25.1 million [19]

Company Overview - Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases [4] - The company's investigational drug, certepetide, aims to enhance the targeting and penetration of anti-cancer drugs in solid tumors through a novel uptake pathway [4] - Lisata has established significant commercial and R&D partnerships based on its CendR Platform® technology [4] Financial Results Announcement - The company will report its financial results for the three months ended March 31, 2025, on May 8, 2025, after the market closes [1] - A conference call will be held at 4:30 p.m. Eastern time on the same day to discuss the financial results [1] Participation in Conference Call - Interested participants must register for the conference call via a provided link and will receive an email with dial-in details [2] - To ensure a smooth experience, participants are encouraged to join the call 15 minutes early [2] Webcast Availability - A live webcast of the conference call will be available on Lisata's website under the Investors & News section [3] - The webcast will be accessible for replay starting two hours after the call and will remain available for 12 months [3] Future Expectations - The company anticipates announcing several milestones over the next 1.5 years and believes its projected capital will support operations into the second quarter of 2026 [4]